We observed the benefit of the combination of protein tumor marker S100B and ctDNA BRAF oncogene in preoperative as well as postoperative peripheral blood samples for identification of patients with resectable melanoma (stage I–III) in high risk of recurrence and unfavorable prognosis. The gene discussed is BRAF; the disease is neoplasm.